Head to Head Survey: HeartBeam (NASDAQ:BEAT) vs. Fulgent Genetics (NASDAQ:FLGT)

HeartBeam (NASDAQ:BEAT) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Risk & Volatility

HeartBeam has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Institutional and Insider Ownership

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares HeartBeam and Fulgent Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Valuation & Earnings

This table compares HeartBeam and Fulgent Genetics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01 million	($0.56)	-1.35
Fulgent Genetics	$322.67 million	1.64	-$60.51 million	($2.39)	-7.82

HeartBeam has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for HeartBeam and Fulgent Genetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1	2	4	1	2.63
Fulgent Genetics	1	2	2	0	2.20

HeartBeam presently has a consensus target price of $4.33, suggesting a potential upside of 471.83%. Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 44.54%. Given HeartBeam’s stronger consensus rating and higher probable upside, research analysts clearly believe HeartBeam is more favorable than Fulgent Genetics.

Summary

HeartBeam beats Fulgent Genetics on 8 of the 14 factors compared between the two stocks.

About HeartBeam

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.